Here’s a startling fact: a commonly prescribed medication could silently damage your vision, and most people have no idea. Hydroxychloroquine (HCQ), widely used to treat conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), has a dark side—retinal toxicity. This isn’t just a minor side effect; it can lead to irreversible vision loss, color blindness, and even a condition called bull’s eye maculopathy. But here’s where it gets controversial: while the overall risk of HCQ retinopathy is around 7.5%, the actual danger might be lurking earlier than we thought, and this is the part most people miss.
A groundbreaking study published in BMC Ophthalmology (https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-025-04247-w) has shed light on a potential early warning sign: changes in the ganglion cell complex (GCC) thickness. HCQ accumulates in retinal ganglion cells (RGCs), causing them to shrink and eventually degenerate. The problem? By the time traditional screening methods detect issues, the damage is often irreversible. But what if we could catch it sooner?
Spectral-domain optical coherence tomography (SD-OCT) might hold the key. This advanced imaging technique can detect localized thinning of retinal layers in the parafoveal zone—a red flag for early toxicity—long before visual field loss or other symptoms appear. The study focused on 87 patients (mostly women) taking HCQ, divided into two groups based on treatment duration: less than 5 years and 5 years or more. Here’s the kicker: both groups showed significantly reduced GCC thickness compared to healthy controls, even in those using HCQ for a shorter period. But does this mean early users are just as at risk? Or is it the cumulative dose that matters?
The findings are eye-opening. Average, superior, and inferior GCC thicknesses were all lower in HCQ users, with focal and global loss volumes (FLV and GLV) also elevated. Yet, surprisingly, no clear correlation was found between GCC thinning and the duration of HCQ use. This raises a provocative question: Could retinal damage begin earlier than we’ve assumed, regardless of how long someone’s been on the medication?
The study’s authors argue that monitoring GCC thickness could be a game-changer for early detection, but they also acknowledge limitations. Without longitudinal data, it’s hard to prove causation, and measuring GCC thickness in only two quadrants (superior and inferior) might not tell the full story. Still, the implications are huge. If confirmed, this could revolutionize how we screen HCQ patients, potentially saving countless eyes from irreversible harm.
But here’s the real question: Are we doing enough to protect patients today? Should HCQ users demand more frequent, advanced screenings? And if so, who should bear the cost? Let’s keep the conversation going—share your thoughts in the comments below. Your perspective could spark a much-needed debate.
